Clinical trial
A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer
NCT00068380 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00068380 |
|---|---|
| Title | A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer |
| Official title | A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Gastric Cancer, Stage IV Gastric Cancer |
| Intervention type | Drug, Other |
| Interventions | imatinib mesylate, laboratory biomarker analysis |
| Enrollment | 17 |
| Start date | Mar 1, 2004 |
| Primary completion | Mar 1, 2010 |
| Completion | Mar 1, 2010 |
| First posted | Sep 11, 2003 |
| Last update posted | Jul 11, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: